Skip to main content

Colorectal Cancer

Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer

By Wayne Kuznar

Immunotherapy, Web Exclusives, Colorectal Cancer

Personalized Care in Colorectal Cancer: Tailoring Treatment and Healthcare Delivery

By Sheetal Kircher, MD; Halla Nimeiri, MD; Julia Trosman, PhD, MBA; Christine Weldon, MBA; Al B. Benson III, MD, FACP, FASCO

Colorectal Cancer

BRAF Mutation in Colorectal Cancer

Anita Turk, MD; Dustin Deming, MD
Division of Hematology and Oncology,Department of Medicine
University of Wisconsin-Madison School of Medicine and Public Health
and University of Wisconsin Car

Colorectal Cancer

Checkpoint Inhibition: A Promising Immunotherapeutic Approach for Colorectal Cancer

Colorectal Cancer

Immunotherapy in Colorectal Cancer: Present and Future

By Beverly E Barton, PhD

Colorectal Cancer

Bevacizumab Not Cost-Effective in Metastatic Colorectal Cancer

Colorectal Cancer

Bevacizumab Improves Survival in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

Predicting Response to EGFR-Targeting mAbs in Colorectal Cancer – Is the KRAS Mutation Test Sufficient?

By Niklas K. Finnberg, PhD

Colorectal Cancer

Bevacizumab Maintenance Improves Survival in mCRC, but Added Erlotinib Is of No Value

By Alice Goodman

Colorectal Cancer

Crizotinib and Colorectal Cancer – A Couple to Be Tested?

By Sebastian Stintzing, MD

Colorectal Cancer

Page 1 of 2

1
2